Related Experiment Video
Updated: May 30, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Long-term prognostic value of myeloperoxidase on acute coronary syndrome: a meta-analysis
Yongle Chen1, Feng Zhang, Lili Dong
1Department of Echocardiography, Zhongshan Hospital of Fudan University, Shanghai, China.
Background And Aims:
Recent studies have shown that myeloperoxidase (MPO) is involved in the pathogenesis of acute coronary syndrome (ACS). However, there were different results in different studies as to whether MPO could predict the long-term adverse outcomes in patients with ACS. In this paper we aimed to investigate the long-term prognostic value of MPO in ACS.
Methods:
We performed a meta-analysis to compare the long-term prognosis of ACS patients with high MPO and low MPO levels. The literature was retrieved by formal searches of electronic databases (PubMed, EMBASE, Medline, OVID, and web of knowledge) from inception to July 2010.
Results:
A total of eight clinical trials were included in this meta-analysis involving 3902 patients. The high MPO level group showed a poorer outcome than the low MPO level group (14.3 vs. 10.4%, risk ratio [RR] 1.84, 95% confidence interval [CI] 1.42-2.37, p <0.00001).
Conclusions:
ACS patients with high MPO levels had a poor long-term prognosis.
Insights
Elevated myeloperoxidase (MPO) levels in acute coronary syndrome (ACS) patients indicate a poorer long-term prognosis. This meta-analysis confirms MPO as a significant predictor of adverse outcomes in ACS.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- Myeloperoxidase (MPO) plays a role in acute coronary syndrome (ACS) pathogenesis.
- Previous studies yielded conflicting results regarding MPO's predictive value for long-term adverse outcomes in ACS patients.
Purpose of the Study:
- To investigate the long-term prognostic value of myeloperoxidase (MPO) in patients diagnosed with acute coronary syndrome (ACS).
Main Methods:
- A meta-analysis was conducted to compare long-term prognoses of ACS patients with high versus low MPO levels.
- Literature search performed across major electronic databases (PubMed, EMBASE, Medline, OVID, web of knowledge) up to July 2010.
Main Results:
- Eight clinical trials involving 3902 patients were included.
- Patients with high MPO levels demonstrated significantly poorer outcomes compared to those with low MPO levels (14.3% vs. 10.4%).
- The risk ratio for adverse outcomes in the high MPO group was 1.84 (95% CI: 1.42-2.37, p < 0.00001).
Conclusions:
- High myeloperoxidase levels are associated with a poor long-term prognosis in patients with acute coronary syndrome.
- MPO serves as a valuable prognostic biomarker for ACS patients.
More Related Videos
05:17Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
Published on: July 28, 2016
08:51Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
Published on: September 20, 2024
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction